A risk-characterization framework for decision-making at the Food and Drug Administration /
With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that co...
| Автор-организации: | National Academies (U.S.). Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II, (Author) |
|---|---|
| Формат: | Електронна книга |
| Език: | English |
| Публикувано: |
Washington D.C. :
National Academies Press,
[2011]
|
| Предмети: | |
| Онлайн достъп: |
http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=372484 |
| Подобни документи: |
Print version::
Risk-characterization framework for decision-making at the Food and Drug Administration. |
Съдържание:
- Introduction
- A Risk-Characterization Framework
- Case Study of a Mitigation-Selection Decision
- Case Study of a Targeting Decision
- Case Study of a Strategic-Investment Decision
- Case Study of a Targeting Decision That Spans Food and Drug Administration Centers
- Conclusions and Future Directions
- A:
- Letter Report on the Development of a Model for Ranking FDA Product Categories on the Basis of Health Risks
- B:
- Statement of Task for the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II
- C:
- Scenarios Provided by the U.S. Food and Drug Administration to the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II
- D:
- Biographic Information on the Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II
- E:
- Factors Hypothesized as Important in Understanding Risk.